Laboratory Corporation Of America ((LH)) has held its Q4 earnings call. Read on for the main highlights of the call.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest earnings call for Laboratory Corporation of America (Labcorp) was marked by an optimistic tone, reflecting strong revenue growth in both the diagnostics and biopharma segments. The company’s strategic acquisitions and collaborations contributed positively to the outlook, although there were some concerns about margin pressures due to recent acquisitions and increased personnel costs.
Revenue Growth
Labcorp reported a robust revenue for the quarter, reaching $3.3 billion, which represents a 10% increase compared to the same period last year. The diagnostics and biopharma sectors each experienced a 10% growth, highlighting the company’s strong performance in these critical areas.
Acquisitions and Strategic Collaborations
The company completed significant acquisitions, including select assets and molecular testing locations of Lab Works, and outreach laboratory services for Ballad Health. Additionally, Labcorp announced a strategic collaboration with Inspira Health, positioning itself for future growth and innovation.
Adjusted EPS Increase
Labcorp’s adjusted earnings per share (EPS) rose to $3.45, marking a 5% increase year-over-year. This improvement underscores the company’s effective financial management and operational efficiency.
Strong Free Cash Flow
The company reported a strong free cash flow from continuing operations, amounting to $665 million for the quarter. This financial strength provides Labcorp with the flexibility to invest in growth opportunities and return value to shareholders.
Launch of New Diagnostic Tests
Innovation continues to be a priority for Labcorp, as evidenced by the introduction of new diagnostic tests, including a multiple sclerosis monitoring profile and a pioneering companion diagnostic assay for identifying gastric cancer patients suitable for targeted treatment.
Expansion in Genetic Testing
Labcorp expanded its leadership in genetic testing solutions through the acquisition of select assets from Invitae. This move enhances Labcorp’s capabilities in providing comprehensive genetic testing services.
Promising 2025 Guidance
For 2025, Labcorp projects enterprise revenue growth of 6.7% to 8%, with expectations of improved margins across diagnostics and biopharma segments. The company anticipates adjusted EPS to range from $15.60 to $16.40, implying a midpoint growth rate of 10%. Free cash flow is expected to grow in line with earnings, estimated between $1.1 billion and $1.25 billion. Despite a headwind from foreign currency translation, Labcorp remains optimistic about its revenue growth.
In conclusion, Labcorp’s earnings call presented a positive outlook with strong growth in key sectors and strategic initiatives. While margin pressures and higher personnel costs are areas of concern, the company’s forward-looking guidance provides confidence in its ability to navigate these challenges and continue delivering value to shareholders.
